Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Improvised Nasal Naloxone Devices Might Deliver Insufficient Medication

By Will Boggs, MD (Reuters Health) | on April 11, 2019 | 0 Comment
Latest News
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Improvised nasal naloxone devices (INND) commonly used by first responders and the general public deliver significantly less naloxone than regulator-approved devices, according to a study from the National Institute on Drug Abuse (NIDA).

You Might Also Like
  • Naloxone Nasal Spray Approved by FDA for Opioid Overdose Treatment
  • Naloxone Distribution to Patients in Emergency Department Raises Controversy
  • Naloxone Distribution Strategies Needed in Emergency Departments

“We definitely know that between the two nasal delivery systems, the improvised device is not as efficient at delivering naloxone to the bloodstream compared to the FDA-approved nasal Narcan spray,” Dr. Philip A. Krieter from NIDA, in Bethesda, Maryland, told Reuters Health by email.

“Using the improvised device twice, two minutes apart, does not come close to reaching the naloxone blood level that is seen after one spray of nasal Narcan. It is important to note that the improvised device is not approved by the FDA,” he said.

The improvised device, consisting of a prefilled naloxone syringe attached to a mucosal atomization device, has been used since 1994 by patients and first responders. In recent years, the U.S. Food and Drug Administration (FDA) has approved Narcan devices for nasal administration of naloxone as well as an autoinjector for intramuscular injection of naloxone, all of which can be used by nonmedical personnel for administering naloxone.

Dr. Krieter’s team compared the pharmacokinetics of the FDA-approved devices and the INND in their study of 30 healthy volunteers of both sexes, 27 of which completed the study.

The peak plasma concentration (Cmax) was highest after intranasal administration of 4 mg of naloxone using the 4-mg FDA-approved Narcan spray device, similar when 2 mg of naloxone were administered using the autoinjector or the 2-mg FDA-approved Narcan spray device, and lowest when 2 and 4 mg were given by one or two intranasal doses using the INND.

The median time to reach Cmax (Tmax) was 20 minutes for all of the intranasal doses and slightly longer after the intramuscular dose, the researchers report in The Journal of Clinical Pharmacology, online March 12.

The total absorption (area under the concentration-time curve [AUC]) was approximately the same when 2 mg of naloxone were given by the autoinjector and 4 mg of naloxone were administered by the 4-mg Narcan spray device, while AUC values were lowest after 2 or 4 mg of naloxone were delivered by the INND.

The relative bioavailability of the intranasal naloxone compared with the intramuscular device was 54 to 62 percent for the Narcan spray devices versus only 19 to 23 percent using the INND.

Exposure during the critical first five, 10, and 20 minutes was approximately two- to three-fold higher using either Narcan spray device or the autoinjector compared with exposure following use of the INND.

Pages: 1 2 3 | Single Page

Topics: Drug AbuseDrug UseNaloxoneOpiod CrisisOpioids

Related

  • Prehospital Buprenorphine Is a Powerful Tool in the Opioid-Crisis Fight

    June 4, 2025 - 0 Comment
  • How to Manage Elderly Patient Pain without Opioids

    February 13, 2024 - 0 Comment
  • Managing Pain Relief in Palliative Care

    July 27, 2021 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

No Responses to “Improvised Nasal Naloxone Devices Might Deliver Insufficient Medication”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603